Iovance Biotherapeutics
IOVA
IOVA
235 hedge funds and large institutions have $1.72B invested in Iovance Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 86 increasing their positions, 70 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
23% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 70
4% more funds holding
Funds holding: 226 → 235 (+9)
3.54% less ownership
Funds ownership: 86% → 82.45% (-3.5%)
Holders
235
Holding in Top 10
5
Calls
$55.3M
Puts
$20.5M
Top Buyers
| 1 | +$40.2M | |
| 2 | +$17.1M | |
| 3 | +$11.5M | |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$8.56M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$8.31M |
Top Sellers
| 1 | -$55.9M | |
| 2 | -$18.7M | |
| 3 | -$13.4M | |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$8.29M |
| 5 |
BHCM
Brevan Howard Capital Management
St. Helier,
Jersey
|
-$7.07M |